Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Launched by MAASTRICHT RADIATION ONCOLOGY · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to find the best treatment for men with aggressive prostate cancer, which is a type of cancer that can be very hard to treat. Researchers will create small, 3D mini-tumors from a patient’s tumor sample. These mini-tumors keep the same characteristics as the original tumor, allowing doctors to test different treatments on them. The goal is to find out which treatment works best for each individual patient, helping to improve survival rates and reduce the chances of cancer coming back.

To participate in this trial, you need to be a man aged 18 or older with prostate cancer. You should also be scheduled for a specific type of treatment called HDR brachytherapy or a prostate biopsy if your cancer has spread. Unfortunately, younger patients or those who cannot provide a tumor sample for testing won't be eligible. If you join the study, you’ll be helping researchers learn more about how to personalize cancer treatment, which could lead to better outcomes for future patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or older
• • Patients with prostate cancer
• • Patients planned for HDR brachytherapy treatment for high-risk or recurrent prostate cancer or transperineal prostate biopsy with MRI-suspected metastatic prostate cancer with at least clinical stage T3-4.
• Exclusion Criteria:
• • Patients younger than 18 years
• • Patients of whom it is not possible to obtain left-over tissue as part of the normal clinical treatment procedure (e.g., if all tumor material is required for the pathologist to make a diagnosis, to stage the patient or to perform a molecular diagnosis).